Table 1 Baseline characteristics of study population
Baseline characteristics (n = 248 patients, 248 tumors) | |
|---|---|
Total | |
Sex (M: F) | 187:61 (75.4:24.6) |
Age (year, mean ± SD) | 66.2 ± 8.4 |
Child-Pugh classification (A/B) | 241/7 |
BCLC stage* | |
Very early (0) | 159/224 (71.0) |
Early (A) | 61/224 (27.2) |
Intermediate (B) | 4/224 (1.8) |
Image modality used for fusion process | |
CT | 36/248 (14.5) |
MRI | 212/248 (85.5) |
Median interval between imaging and procedure (days, range) | 24 [0–63] |
Tumor location | |
Left lobe (S2, S3, S4) | 62/248 (25.0) |
Right superior segments (S7, S8) | 99/248 (40.0) |
Right inferior segments (S5, S6) | 87/248 (35.1) |
Tumor size (cm, mean ± SD) | 1.6 ± 0.6 |
< 2 cm | 168/248 (67.7) |
≥ 2 cm, < 2.5 cm | 64/248 (25.8) |
≥ 2.5 cm | 16/248 (6.5) |
Tumor diagnosis | |
HCC | 223/248 (89.9) |
Liver metastasis | 23/248 (9.3) |
Other malignancies | 2/248 (0.8) |
Tumor nature | |
De novo tumor | 67/248 (27.0) |
Recurred tumor | 181/248 (73.0) |
Underlying liver disease | |
Alcoholic liver disease | 8/248 (3.2) |
HBV | 177/248 (71.4) |
HCV | 21/248 (8.5) |
Others | 42/248 (16.9) |
Previous treatment for HCC | |
RFA | 114/248 (46.0) |
TACE | 110/248 (44.4) |
PEIT | 16/248 (6.5) |
Surgical resection | 51/248 (20.6) |
Insertion of artificial ascites | 212/248 (85.5) |
Major complications** | 0/248 (0) |
Median follow up period (months, range) | 14.6 [0-31.3] |
Mean procedure time (minutes, range) | 7.8 [2-22.5] |